Acrux reports progress in development of Testosterone MD-Lotion(R) for men

September 07, 2005

Acrux Limited (ASX: ACR), the Australian pharmaceutical company which specialises in administering drugs through the skin, today announced positive results from two more clinical studies of its Testosterone MD-Lotion® treatment for testosterone deficiency in men, which is associated with a number of symptoms including lethargy, depression and reduced libido. Both studies were conducted at the Centre for Clinical Studies, Melbourne, with Professor Susan Davis supervising as Principal Investigator.

The studies compared blood levels of testosterone in healthy volunteers. The aim of the first study was to compare two different formulations of Testosterone MD Lotion®, and the aim of the second study was to compare two different application sites.

The results of the first study showed that both formulations provided similar blood levels, providing options for continued development of either formulation. In the second study, there was a significant difference in absorption between the two different application sites, providing important information for the design of the remaining clinical studies in men.

In both studies, the lotion was well tolerated, with no application site reactions noted, and no serious adverse events recorded. Full details of the studies are presented in Appendix 1.

Acrux's development of Testosterone MD Lotion® is continuing, with further studies to commence shortly to confirm the doses required to maintain testosterone blood levels in the target range for effective treatment.

Acrux CEO and Managing Director, Dr Igor Gonda said: "We believe our fast drying, no-touch metered dose lotion has significant competitive advantage over the existing products in this growing market. The remaining trials suit our expertise and require moderate investment, so in line with our financial plans we intend to complete them ourselves before choosing the best option for sales and marketing".

The remaining development programme:
The three remaining clinical studies will involve measuring the amount of drug delivered to the bloodstream ("pharmacokinetics"), following advice from the US Food and Drug Administration (FDA). This means that the programme is more straightforward and has lower risk and lower cost than a traditional clinical study programme. Acrux plans to complete all remaining development, using its own expertise and experience in pharmacokinetic studies. A New Drug Application is targeted for mid-2008 to obtain FDA approval to market the product in the USA. The next clinical study will commence later this year. This study will assess testosterone blood levels in male volunteers after multiple doses of Testosterone MD-Lotion®, with completion of the study planned for early 2006.

The target market:
It is estimated that four to five million men suffer from low testosterone (hypogonadism) in the USA alone, with this figure predicted to increase in future years. Global sales in the year to January 2005 of products to treat hypogonadism were US $415 million, representing an increase of 12% over the previous year (IMS Health, IMS Midas, MAT, Jan 2005).
-end-
Contacts:
Igor Gonda, CEO & Managing Director
Tel: 61-3-8379-0100

Geoff Harrison
RADAR Investor Relations
Tel: 61-2-8256-3333

About Acrux
www.acrux.com.au Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin.

Acrux's product pipeline includes treatments of hormonal deficiencies, pain and central nervous system disorders, as well as a contraceptive.

19 human clinical trials have been completed with 7 different drug products and the lead product, EvamistTM (Estradiol MDTS®), is currently in a phase 3 clinical trial in the USA.

Acrux has licensed USA rights for EvamistTM (Estradiol MDTS®) and Testosterone MDTS® to VIVUS and AUS/NZ distribution rights for Testosterone MDTS® and Fentanyl MDTS® to CSL Limited. Acrux has also licensed its technology to Eli Lilly for veterinary healthcare products, to Napa Biosciences for certain dermatology products and to Connetics for anti-psoriatics and local anaesthetics.

Research Australia

Related Testosterone Articles from Brightsurf:

ACP issues guideline for testosterone treatment in adult men with age-related low testosterone
Physicians should prescribe testosterone for men with age-related low testosterone only to treat sexual dysfunction, the American College of Physicians (ACP) says in a new evidence-based clinical practice guideline.

Women with asthma appear more likely to have lower levels of testosterone
Women with asthma appear more likely to have lower levels of 'free' (not attached to proteins) testosterone than women who do not have asthma, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Penis development needs more than just testes and testosterone
Proper development of the fetal penis requires not just testosterone from the testes, but a second hormone produced by other tissues, including the placenta, according to a new study publishing Feb.

Testosterone treatment over 10 years can improve or reverse type 2 diabetes in men with low testosterone, and induce significant weight loss
New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) reveals that in men with low testosterone who have type 2 diabetes (T2D), testosterone therapy can improve their disease and reverse its progress, and can also induce significant weight loss.

Testosterone replacement therapy may slow the progression of COPD
GALVESTON, Texas -- Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.

Testosterone research brings new hope for cancer patients
Approximately 20 percent of cancer related deaths are attributed to the syndrome of cachexia.

Testosterone prescriptions have sharply dropped in the past few years
Testosterone use in the United States tripled between 2001 and 2011, mostly in men without a clear indication for it.

Use of prescribed testosterone therapy in US decreases in recent years
Testosterone use in the United States tripled from 2001 through 2011, mostly in men without a clear indication.

Testosterone causes men to desire luxury goods
Researchers examine testosterone's effect on men's desire for goods that are considered to have social cachet.

Men's testosterone levels largely determined by where they grow up
Men's testosterone levels are largely determined by their environment during childhood, according to new research.

Read More: Testosterone News and Testosterone Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.